Skip to main navigation

Skip to content
Skip to primary sidebar

Materials for Veloxis Shareholders and Warrantholders Regarding Recommended Conditional Voluntary Public Offer from Asahi Kasei Pharma Denmark A/S
Dokumenter til Veloxis aktionærer og warrantindehavere angående anbefalet offentligt betinget frivilligt købstilbud fra Asahi Kasei Pharma Denmark A/S

Back to the Corporate Site

Back to the Corporate Site

Investor Relations

IR Menu

News & Releases
Download Center
Calendar
Corporate Governance
Financial Information
- Outlook
Stock Information
General Meetings

Governance Documents

Governance Documents

Governance Statements

Statutory Corporate Governance Report for 2018, cf. art. 107b of the Danish Financial Statements Act 1.4 MB

Statutory Corporate Governance Report for 2017, cf. art. 107b of the Danish Financial Statements Act 718.5 KB

Statutory statement of corporate governance, cf. section 107b of the Danish Financial Statements Act (2016) 681.6 KB

Statutory statement of corporate governance, cf. section 107b of the Danish Financial Statements Act (2015) 496.8 KB

Statutory statement of corporate governance, cf. section 107b of the Danish Financial Statements Act (2014) 500.2 KB

Statutory statement of corporate governance, cf. section 107b of the Danish Financial Statements Act (2013) 401.4 KB

Veloxis Corporate Governance 2011 - English 518.5 KB

Statutory statement of corporate governance, cf. section 107b of the Danish Financial Statements Act (2012) 671.1 KB

Statutory statement of corporate governance, cf. section 107b of the Danish Financial Statements Act (2011) 694.7 KB

Statutory statement of corporate governance, cf. section 107b of the Danish Financial Statements Act (2012) 500.9 KB

US Compliance Statements

Code of Business Conduct 866.5 KB

US Compliance Statements

To request a summary of the Veloxis Comprehensive Compliance Program, please call +1 919 591 3090. 101.4 KB

Documents

Articles of Association 493.7 KB

Remuneration Committee Charter 82.8 KB

Audit Committee Charter 398.2 KB

Remuneration Policy 100.1 KB

Rules of Procedure for the Board of Directors 198.9 KB

Efforts by Veloxis to Obtain Final Approval for Envarsus® XR from the Food and …

IR Policy 173.6 KB

Submenu - Corporate Governance

Corporate Governance
Governance Documents
Risk Management
Reporting Compliance
Violations and Concerns
Whistleblower Policy
Guidelines for Reported Employees

Shareholder Portal

Enter Veloxis portal for existing shareholders.

Latest News & Releases

Jan 24, 2020

Notice to Convene Extraordinary General Meeting

Jan 24, 2020

Announcement of Request for Delisting of Veloxis Pharmaceuticals A/S' Shares from Nasdaq Copenhagen

© 2020 All rights reserved. Veloxis Pharmaceuticals Inc. ENV-18-090.0 06/18

info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET

Sitemap | Contact | Privacy Policy | Disclaimer